Alaunos Therapeutics, Inc.
TCRT
$1.89
-$0.175-8.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 66.67% | 80.00% | -60.00% | -99.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 66.67% | 80.00% | -60.00% | -99.79% |
| Cost of Revenue | -87.97% | -94.10% | -97.77% | -92.51% | -78.43% |
| Gross Profit | 88.08% | 94.20% | 97.82% | 92.54% | 75.26% |
| SG&A Expenses | -59.91% | -66.36% | -63.51% | -52.49% | -30.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -70.08% | -79.71% | -83.08% | -76.18% | -61.53% |
| Operating Income | 70.11% | 79.75% | 83.11% | 76.19% | 58.05% |
| Income Before Tax | 79.13% | 84.79% | 86.68% | 67.68% | 48.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 79.13% | 84.79% | 86.68% | 67.68% | 48.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.13% | 84.79% | 86.68% | 67.68% | 48.06% |
| EBIT | 70.11% | 79.75% | 83.11% | 76.19% | 58.05% |
| EBITDA | 67.93% | 78.03% | 81.63% | 74.73% | 57.22% |
| EPS Basic | 79.38% | 84.80% | 86.70% | 68.32% | 50.41% |
| Normalized Basic EPS | 69.92% | 80.63% | 84.08% | 78.41% | 63.71% |
| EPS Diluted | 79.38% | 84.80% | 86.70% | 68.92% | 51.32% |
| Normalized Diluted EPS | 69.92% | 80.63% | 84.08% | 78.41% | 63.71% |
| Average Basic Shares Outstanding | 1.20% | 0.04% | 0.09% | 1.88% | 4.63% |
| Average Diluted Shares Outstanding | 1.20% | 0.04% | 0.09% | 1.88% | 4.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |